Exicure, Inc. (NASDAQ:XCUR) Sees Significant Drop in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the target of a significant drop in short interest in the month of May. As of May 29th, there was short interest totaling 20,834 shares, a drop of 35.5% from the May 14th total of 32,290 shares. Based on an average daily trading volume, of 14,468 shares, the short-interest ratio is presently 1.4 days. Approximately 0.7% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Exicure currently has an average rating of “Sell”.

Exicure Price Performance

Shares of XCUR opened at $2.79 on Tuesday. Exicure has a one year low of $2.62 and a one year high of $9.50. The company has a 50-day simple moving average of $3.31 and a two-hundred day simple moving average of $4.34. The firm has a market capitalization of $17.77 million, a PE ratio of -1.80 and a beta of 3.53.

Exicure (NASDAQ:XCUR) last issued its quarterly earnings data on Friday, May 29th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($18.60) by $18.31.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.